Loading...
Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2(V617F) cells
The JAK/STAT pathway is constitutively activated in myeloproliferative neoplasms and can be inhibited by ruxolitinib, a selective JAK1/2 inhibitor. The JAK2(V617F) mutation leads to constitutive STAT3 phosphorylation and potentially leads to inhibition of Stathmin 1 activity via STAT3. In support of...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4745747/ https://ncbi.nlm.nih.gov/pubmed/26356819 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|